Companies › Rege Nephro
1 active drug program in 2 registered trials: 2 Phase 2; Cardiovascular, Genitourinary.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tamibarotene Retinoic acid receptor beta agonist; Retinoic acid receptor alpha agonist | RARB, RARA | Phase 2 | Autosomal Dominant Polycystic Kidney Disease (ADPKD); HFpEF - Heart Failure With Preserved Ejection Fraction | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06289998 | Tamibarotene | Phase 2 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Genitourinary | Dec 2025 |
| NCT07855692 | Tamibarotene | Phase 2 | HFpEF - Heart Failure With Preserved Ejection Fraction | Cardiovascular | May 2029 |
Noorik Biopharmaceuticals Tectonic Operating Company CuraSen Therapeutics Neurimmune Kira Pharmacenticals (US)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.